Court Square Capital Partners has closed its fifth flagship fund at approximately $3.8bn, significantly exceeding its $3bn target and marking the largest vehicle in the firm’s history, according to a report by the Wall Street Journal.
Sports-focused private equity firm 154 Partners has completed fundraising for its inaugural fund, reaching its $400m hard cap as it looks to capitalise on opportunities across the broader sports ecosystem, according to a report by Bloomberg.
Percheron Capital (Percheron), a private equity firm focused on essential services, has closed its third fund, Percheron Capital Fund III (Fund III), with approximately $3.1bn in total commitments.
Jeito Capital, an independent European private equity firm specialising in biopharma investments, has closed its second fund, Jeito II, at a record €1bn ($1.2bn billion), tripling the firm’s assets under management to €1.6bn.
Blackstone has closed its latest flagship opportunistic credit fund – Blackstone Capital Opportunities Fund V (COF V) – with more than $10bn in total capital commitments, reaching its hard cap amid strong investor demand for private credit strategies.
Growth-focused private equity firm OceanSound Partners has completed the final close of its third fund, OceanSound Partners Fund III, LP, with $3.0bn in capital commitments plus an additional $0.4bn for related co-investment vehicles.
BC Partners has raised approximately €2.2bn ($2.5bn) in initial commitments for its latest flagship vehicle, Fund XII, putting the firm nearly halfway to its target of €5bn, according to a report by Bloomberg citing unnamed sources familiar with the matter.
17Capital has completed the final close of Credit Fund 2 at approximately $7.5bn, including affiliated mandates, marking the largest fundraise for a NAV loan vehicle to date and bringing the firm’s total capital raised across eight funds since 2008 to more than $24bn.
Blackstone Inc has raised $6.3bn for its latest life-sciences fund, Blackstone Life Sciences VI, marking the firm’s largest capital raise for backing late-stage clinical trials of drugs and medical technologies, according to a report by Bloomberg.
Carlyle Group is reportedly planning a new fund targeting the defence sector as US and European governments ramp up military modernisation, according to a report by Bloomberg citing unnamed sources familiar with the matter.
12 November, 2026 – 5:00 pm
12 November, 2026 – 8:00 am
12 February, 2026 – 8:00 am
12 February, 2026 – 5:00 pm
